Alvogen is a global, privately owned pharmaceutical company focused on developing, manufacturing and selling generic, brand, over-the counter (OTC) and biosimilar products for patients around the world. With commercial footprint in over 20 markets, Alvogen’s key regions include the U.S. and APAC regions.

Alvogen's product portfolio consists of a broad range of leading molecules for the treatment of conditions in the areas of oncology, cardiology, respiratory, neurology and gastroenterology, in addition to a fast-growing portfolio of biosimilars, brands and OTC products.

Róbert Wessman‘s business plan for Alvogen was originally scribbled on a napkin in a New York restaurant back in 2009 in the middle of one of the worst financial crises in history when access to capital was virtually non-existent.

Our true purpose as a company is to make people's lives better by producing high quality medicines that help people live longer, healthier and more active lives and making them more accessible to those who might not otherwise be able to afford them.

At Alvogen, we value partnerships and collaboration. Our future strategy relies heavily on our strategic selection of people and successful partnerships around the world.